Vimarsana
Biggest News Aggregation in the World

Page 5 - Equity Plan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equity Plan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equity Plan Today - Breaking & Trending Today

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 10, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the...

BioNTech : Invitation to the Annual General Meeting 2024 - Form 6-K -April 08, 2024 at 05:10 pm EDT - Vimarsana News

BioNTech : Invitation to the Annual General Meeting 2024 - Form 6-K -April 08, 2024 at 05:10 pm EDT

Invitation to the Annual General Meeting 2024 Unique identifier of the event: 2008339965e7ee11b53000505696f23c Ladies and Gentlemen, ...

Vote April 2: Meet the Candidates For City Office - Vimarsana News

Vote April 2: Meet the Candidates For City Office

And read the analysis of each race and bios for each candidate.

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., April 01, 2024 -- Biomea Fusion, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with...